Last updated: July 31, 2026
Desyrel is the former brand name for trazodone hydrochloride, an oral serotonin antagonist and reuptake inhibitor approved in the United States for major depressive disorder. The original immediate-release product has lost regulatory and patent exclusivity. Current commercial activity is concentrated in low-cost generic trazodone tablets and, to a lesser extent, extended-release formulations such as Oleptro. No active, brand-specific Desyrel development program or material Orange Book patent barrier is evident. Market growth is likely to come from generic volume, off-label sleep use, and clinical research in neuropsychiatric and sleep disorders rather than from premium branded sales.
What is Desyrel and how is trazodone used?
Desyrel contains trazodone hydrochloride, a centrally acting compound with serotonin 5-HT2A antagonism and serotonin reuptake inhibition. The FDA approved trazodone for major depressive disorder, although current prescribing is heavily concentrated in lower-dose off-label use for insomnia, particularly when depression, anxiety, or other psychiatric conditions coexist. The FDA-approved labeling covers depressive illness rather than primary insomnia. [1]
| Attribute |
Desyrel and trazodone |
| Active ingredient |
Trazodone hydrochloride |
| Drug class |
Serotonin antagonist and reuptake inhibitor |
| Original indication |
Major depressive disorder |
| Common current use |
Depression, insomnia, anxiety-associated sleep disturbance |
| Dosage forms |
Immediate-release tablets; extended-release tablets in certain markets |
| U.S. brand status |
Original Desyrel brand no longer represents the principal commercial product |
| Main competitors |
Generic trazodone, mirtazapine, low-dose doxepin, zolpidem, suvorexant, lemborexant |
| Key safety concerns |
Suicidality warning in younger patients, serotonin syndrome, orthostatic hypotension, QT prolongation, priapism, sedation |
Trazodone’s low acquisition cost and sedating pharmacology have preserved demand despite competition from newer antidepressants and insomnia products. Its use for insomnia is widespread but remains off-label in the United States.
What is the FDA regulatory status of Desyrel?
The original Desyrel product was approved decades ago and is no longer the principal U.S. commercial presentation. FDA-approved trazodone products remain available through abbreviated new drug applications, or ANDAs, from multiple manufacturers. FDA labeling for generic trazodone continues to identify major depressive disorder as the approved indication. [1]
The FDA has not granted trazodone a new molecular entity exclusivity period in the modern regulatory era. The product’s regulatory position is therefore based on established safety and efficacy data, generic approvals, and individual manufacturer applications.
Is Desyrel still sold in the United States?
The Desyrel name has limited commercial relevance in the U.S. market. Pharmacies generally dispense trazodone hydrochloride tablets manufactured by generic suppliers. Availability varies by strength, supplier, wholesaler inventory, and pharmacy purchasing agreements.
Extended-release trazodone was commercialized under the Oleptro brand, not as the original Desyrel immediate-release product. Oleptro was developed to provide once-daily dosing and a modified-release profile, but the commercial opportunity was limited by generic immediate-release competition and low-cost alternatives.
What patents protect Desyrel and trazodone?
The original composition-of-matter and early formulation protection for trazodone expired many years ago. Immediate-release trazodone tablets do not have a meaningful surviving U.S. patent estate that prevents routine generic entry.
What is the Orange Book status of Desyrel?
The FDA Orange Book identifies approved trazodone products and their therapeutic-equivalence status, but the original Desyrel product does not provide a current patent-based barrier comparable to an active branded antidepressant. Generic trazodone tablets are generally approved through ANDA pathways and can compete on an AB-rated basis where the applicable reference product and product specifications support substitution. [2]
| Protection category |
Current commercial significance |
| Original trazodone compound patents |
Expired |
| Early immediate-release formulation patents |
Expired |
| Desyrel brand protection |
Trademark and commercial recognition only; no meaningful exclusivity |
| Generic trazodone ANDA approvals |
Active source of market competition |
| Extended-release formulation patents |
Historical protection; no durable barrier to immediate-release generic entry |
| Method-of-use patents |
Limited commercial impact for established depression use; off-label uses generally do not create broad enforceable market exclusivity |
Patent protection for an extended-release formulation does not block generic immediate-release trazodone. A manufacturer seeking an extended-release product may face formulation-specific patent and regulatory issues, but those issues do not restrict the broader immediate-release market.
When did Desyrel lose exclusivity?
Desyrel lost practical exclusivity decades ago. Trazodone entered the market before current Hatch-Waxman exclusivity periods became the principal commercial framework for modern branded medicines. The compound and original product patents have expired, allowing multiple manufacturers to market generic tablets.
The relevant timeline is:
| Period |
Event |
| 1980s |
Trazodone introduced in the United States for depression |
| 1990s onward |
Generic trazodone becomes available |
| 2000s |
Generic competition expands across multiple strengths |
| 2010 |
Extended-release trazodone marketed as Oleptro |
| 2010s onward |
Generic immediate-release products remain the dominant U.S. supply |
| Current |
No effective Desyrel patent barrier to generic immediate-release entry |
Because the underlying exclusivity has expired, the relevant commercial risks are manufacturing interruptions, product recalls, supplier consolidation, and reimbursement pressure rather than Paragraph IV litigation over the original brand.
Are there Paragraph IV challenges to Desyrel?
Paragraph IV litigation has little current relevance to original Desyrel. A Paragraph IV certification challenges a listed patent for a reference-listed drug. Since the core immediate-release Desyrel patents are expired or no longer commercially controlling, new generic entry does not depend on defeating an active Desyrel patent estate.
The more relevant historical patent issue involved extended-release trazodone products. A generic company developing a modified-release version could evaluate formulation patents, expiration dates, and potential non-infringement or invalidity positions. That analysis is separate from generic immediate-release trazodone.
No active, high-value Paragraph IV dispute is central to the current Desyrel market based on the publicly established status of the product.
What clinical trials are evaluating trazodone?
There is no major clinical-trial program for the discontinued Desyrel brand itself. Current research evaluates trazodone as a low-cost generic active ingredient in other clinical settings.
What are the principal research areas?
Clinical investigations involving trazodone have focused on:
- Sleep disturbance and insomnia
- Sleep problems associated with neurodegenerative disease
- Behavioral symptoms in dementia
- Depression in older adults
- Agitation and psychiatric symptoms
- Traumatic brain injury and neurological recovery
- Sleep architecture and circadian disorders
- Comparative effectiveness against other sedating antidepressants
The clinical development profile is fragmented. Most studies are investigator-sponsored, academic, or exploratory rather than part of a centralized commercial program. ClinicalTrials.gov records identify studies by the active ingredient, not necessarily by the Desyrel brand. [3]
Does trazodone have an FDA-approved insomnia indication?
No. Trazodone is commonly prescribed for insomnia, but the FDA-approved indication remains major depressive disorder. The American Academy of Sleep Medicine has not positioned trazodone as a preferred evidence-based treatment for chronic insomnia because clinical evidence is limited relative to approved insomnia medicines. [4]
This distinction creates a regulatory limitation. A sponsor would need new clinical evidence and an FDA submission to obtain an insomnia indication. Generic manufacturers have little economic incentive to fund such a program because an indication-specific approval would not create broad molecule-level exclusivity after patent expiration.
What is the market size for Desyrel and generic trazodone?
Desyrel-specific revenue is not separately reported in a reliable public manner because the branded product has limited commercial presence and trazodone is sold primarily through generic channels. Market estimates should therefore address the broader trazodone hydrochloride market rather than the Desyrel brand.
The market is characterized by:
- Low unit pricing.
- High prescription volume.
- Multiple manufacturers.
- Limited differentiation among immediate-release tablets.
- Strong substitution pressure from pharmacy benefit managers.
- Demand from both psychiatric and off-label sleep prescribing.
What drives trazodone market demand?
The main demand drivers are:
- Continued use of generic antidepressants.
- Widespread off-label prescribing for insomnia.
- Use in older adults when clinicians seek a sedating alternative to benzodiazepines.
- Low cost compared with branded insomnia drugs.
- Availability in multiple tablet strengths.
- Familiarity among primary-care and psychiatric prescribers.
Demand is constrained by adverse-effect concerns, limited evidence for chronic insomnia, competition from newer antidepressants, and the availability of approved insomnia therapies.
Trazodone competitive landscape
| Drug or class |
Competitive position versus trazodone |
| Mirtazapine |
Competes in depression with insomnia and appetite loss; often more associated with weight gain |
| Low-dose doxepin |
FDA-approved for insomnia; less broad antidepressant use at low doses |
| Zolpidem |
Strong insomnia competitor; controlled-substance and dependence concerns |
| Suvorexant and lemborexant |
Branded orexin antagonists with higher prices and active exclusivity considerations |
| SSRIs and SNRIs |
Strong first-line depression competition but generally less sedating |
| Quetiapine |
Off-label sleep competitor with greater metabolic and antipsychotic safety concerns |
| Melatonin products |
Over-the-counter competition for mild sleep symptoms |
Trazodone retains an important cost advantage, but the product has limited ability to capture premium pricing or defend share through differentiation.
What is the trazodone market forecast through 2030?
A reasonable base-case forecast is for low-single-digit annual growth in global trazodone sales through 2030, measured primarily in prescription volume rather than price. Revenue growth is likely to remain below volume growth because generic pricing will continue to decline.
| Scenario |
2025-2030 volume outlook |
Revenue outlook |
Principal assumptions |
| Downside |
Flat to 1% annual growth |
Decline of 2% to 5% annually |
Price erosion, supply consolidation, stronger use of newer sleep drugs |
| Base case |
2% to 4% annual growth |
Flat to 2% annual growth |
Stable depression use and continued off-label insomnia prescribing |
| Upside |
4% to 6% annual growth |
2% to 4% annual growth |
Positive evidence in dementia-related sleep disorders or new differentiated formulations |
These are scenario estimates for the active-ingredient market, not audited forecasts for the Desyrel brand. The base case assumes no new FDA-approved indication and no premium branded relaunch.
A meaningful upside case would require one of three developments: a clinically differentiated formulation, a new indication supported by controlled trials, or a commercial partnership that improves adherence and targets a defined patient population. None is inherent in the current Desyrel product.
What generic launch risks exist for trazodone?
Generic entry risk is already realized rather than prospective. The market has multiple generic suppliers, so additional launches would primarily redistribute share.
The major business risks are:
- API sourcing concentration, particularly for low-margin products.
- Manufacturing-site disruptions.
- FDA warning letters or recalls.
- Shortages involving specific strengths or tablet sizes.
- Wholesaler and pharmacy contracting pressure.
- Product discontinuation by smaller suppliers.
- Low profitability that discourages redundant manufacturing capacity.
The principal IP barrier is weak. Manufacturing quality, supply reliability, and cost control are more important than patent clearance.
What geographic markets offer opportunity?
The United States remains a large prescription market, but generic pricing limits revenue. Europe and other developed markets have established trazodone use, including branded and generic products. Opportunities in emerging markets depend on local registration, reimbursement, distribution, and physician familiarity.
Geographic commercial considerations include:
| Region |
Market characteristics |
| United States |
Large generic volume; low prices; widespread off-label insomnia use |
| Europe |
National reimbursement controls; country-specific brand and generic competition |
| Japan |
Regulatory and prescribing requirements differ; local formulation and approval strategy matter |
| Latin America |
Variable generic penetration and private-market pricing |
| Asia-Pacific |
Growth potential from expanding psychiatric diagnosis and healthcare access, offset by local competition |
A manufacturer cannot assume that U.S. approval or historical Desyrel branding creates meaningful exclusivity in other jurisdictions. Patent, trademark, regulatory, and data-exclusivity analysis must be conducted country by country.
What is the investment outlook for Desyrel?
Desyrel is unlikely to support a conventional branded pharmaceutical investment thesis. The commercial case is more suitable for:
- Low-cost generic manufacturing.
- Contract manufacturing and supply agreements.
- Hospital and institutional tenders.
- Selected extended-release or abuse-deterrent formulation strategies.
- Combination products with a clinically differentiated delivery profile.
- Licensing of new indications supported by proprietary clinical data.
A relaunch based only on the Desyrel name would face weak differentiation, limited pricing power, and intense generic substitution. A reformulated product could create value only if it demonstrates measurable advantages in tolerability, adherence, next-day sedation, dosing convenience, or a defined patient population.
Key Takeaways
- Desyrel is the former brand name for trazodone hydrochloride.
- The original immediate-release product has no meaningful surviving U.S. patent barrier.
- Generic trazodone is the principal commercial product.
- Trazodone remains FDA-approved for major depressive disorder, not insomnia.
- Clinical research continues, but there is no major brand-specific Desyrel development program.
- Market growth should be measured through generic prescription volume, not branded revenue.
- Base-case revenue growth through 2030 is likely to remain limited because of price erosion.
- Generic launch risk is low from an IP perspective and high from a supply-chain and margin perspective.
- A commercially attractive opportunity would require a differentiated formulation, new indication, or controlled-distribution strategy.
FAQs
Is Desyrel the same as trazodone?
Yes. Desyrel is a historical brand name for trazodone hydrochloride. Most current prescriptions are dispensed as generic trazodone.
Can a generic company launch trazodone without a Paragraph IV challenge?
Yes, where no unexpired listed patent blocks the relevant product. Immediate-release trazodone has long been subject to generic competition, so a new entrant would generally focus on ANDA requirements, product equivalence, manufacturing, and commercial supply.
Is trazodone safer than zolpidem for long-term insomnia?
The answer depends on the patient and clinical context. Trazodone is not a controlled substance in the United States, but it can cause sedation, orthostatic hypotension, arrhythmia risk, and other adverse effects. It also lacks an FDA insomnia indication. Comparative safety must be evaluated using patient-specific factors.
Could a new trazodone formulation obtain market exclusivity?
A new formulation could potentially obtain patent protection if it is novel and non-obvious. Regulatory exclusivity would depend on the approval pathway and the extent of new clinical evidence. Such protection would apply to the formulation or approved use, not necessarily to generic immediate-release trazodone.
Does trazodone have biosimilar competition?
No. Trazodone is a small-molecule drug, not a biologic. The relevant competitive pathway is generic ANDA approval, not biosimilar approval under the Biologics Price Competition and Innovation Act.
References
-
U.S. Food and Drug Administration. (2023). Trazodone hydrochloride tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
National Library of Medicine. (2024). ClinicalTrials.gov: Trazodone studies. U.S. National Library of Medicine.
-
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine, 13(2), 307-349.
